dipyridamole and trametinib

dipyridamole has been researched along with trametinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Bi, F; Tang, Q; Xia, H; Xu, H; Zhou, S	1

Other Studies

2 other study(ies) available for dipyridamole and trametinib

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway. Molecular cancer therapeutics, 2020, Volume: 19, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dipyridamole; Female; Humans; Hydroxymethylglutaryl-CoA Synthase; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidinones; Transfection	2020

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway.

Molecular cancer therapeutics, 2020, Volume: 19, Issue:1

Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dipyridamole; Female; Humans; Hydroxymethylglutaryl-CoA Synthase; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidinones; Transfection

2020